PADI4 and Parkinson disease: Interestingly in vitro pharmacological PAD inhibition in PD-derived fibroblasts showed that the pan-PAD-inhibitor Cl-amidine reduces histone H3 deimination and pro-inflammatory chemokine expression [26], while such PAD inhibition has been shown to disrupt neutrophil extracellular trap (NET) formation also in other disease models [44].